Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 7 sales; 713 institutions reported holding it in 13F filings for Q2 2026, worth $10.6B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $15.8M in total
- 7
- 13F holdersQ2 2026, +49 vs. previous quarter
- 713
- 13F valueReported value at the end of Q2 2026
- $10.6B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding HALO, Q2 2026
No superinvestor reported holding HALO at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Halozyme Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)5:19 PM ET | Sep 16 | 1 day | Posard Matthew L.Director | SSale | −19.0K | $107.74 | −$2.05M | −24.4%58.8K after | 4 lots10b5-1 |
| Sep 11, 2026 (view filing)8:35 PM ET | Sep 9-11 | 2 days | Torley HelenPRESIDENT AND CEO | SSale | −60.0K | $107.28 | −$6.44M | −7.2%767.8K after | 7 lots10b5-1 |
| Aug 19, 2026 (view filing)8:01 PM ET | Aug 17-19 | 2 days | Torley HelenPRESIDENT AND CEO | SSale | −60.0K | $104.59 | −$6.28M | −7.2%767.8K after | 11 lots10b5-1 |
| Aug 11, 2026 (view filing)5:43 PM ET | Aug 10 | 1 day | Connaughton BernadetteDirector | SSale | −1.63K | $102.80 | −$167.2K | −3.9%40.4K after | 10b5-1 |
| Jul 9, 2026 (view filing)5:19 PM ET | Jul 8 | 1 day | Torley HelenPRESIDENT AND CEO | SSale | −1.92K | $79.77 | −$153.4K | −0.2%767.8K after | 2 lots10b5-1 |
| Jul 2, 2026 (view filing)4:42 PM ET | Jul 1 | 1 day | Connaughton BernadetteDirector | SSale | −1.63K | $76.71 | −$124.7K | −3.7%42.0K after | 2 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Krishnan MaheshDirector | SSale | −7.30K | $75.00 | −$547.8K | −33.6%14.5K after | 10b5-1 |
| Jun 3, 2026 (view filing) | Jun 1-3 | 2 days | Torley HelenPRESIDENT AND CEO | SSale | −50.0K | $67.40 | −$3.37M | −6.1%767.8K after | 9 lots10b5-1 |
| Jun 2, 2026 (view filing) | Jun 1 | 1 day | Connaughton BernadetteDirector | SSale | −1.63K | $66.21 | −$107.6K | −3.6%43.7K after | 10b5-1 |
| May 13, 2026 (view filing) | May 11-13 | 2 days | Torley HelenPRESIDENT AND CEO | SSale | −50.0K | $68.68 | −$3.43M | −6.1%767.8K after | 12 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Halozyme Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 13,271,095 | $1.05B | 0.02% | +6,0420.0% | Added |
| State Street Corp | 5,179,434 | $424.6M | 0.01% | +241,580+4.9% | Added |
| Vanguard Capital Management LLC | 5,351,312 | $418.8M | 0.01% | +80,094+1.5% | Added |
| Vanguard Portfolio Management LLC | 5,299,008 | $414.8M | 0.02% | +49,802+0.9% | Added |
| Invesco Ltd. | 3,177,997 | $248.7M | 0.02% | −834,497−20.8% | Reduced |
| Morgan Stanley | 2,832,594 | $225.2M | 0.01% | +270,285+10.5% | Added |
| Boston Partners | 2,773,568 | $216.8M | 0.19% | +89,885+3.3% | Added |
| Bank of America Corp | 2,740,561 | $214.5M | 0.01% | −172,548−5.9% | Reduced |
| Geode Capital Management, LLC | 2,519,951 | $197.3M | 0.01% | +14,165+0.6% | Added |
| William Blair Investment Management, LLC | 2,511,050 | $196.5M | 0.59% | −14,925−0.6% | Reduced |